Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review

Vaccine

Volumn 31, Issue 21, 2013, Pages 2506-2516

  Schillie, Sarah F ^a   Murphy, Trudy V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis B; Immunization; Infant; Neonate; Seroprotection; Vaccine

Indexed keywords

B HEPAVAC II; BETAGEN; BUTANG; ENIVACHB; H B VAX II; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HEPAVAXGEN; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; BIRTH WEIGHT; DRUG EFFICACY; GROUPS BY AGE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84877832031     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.012     Document Type: Review

References (76)

1. IOM (Institute of Medicine) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C 2010, The National Academies Press, Washington, DC.
2. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005 Dec 23, 54(RR-16):1-31.
3. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods 1987, 17(August (1-2)):69-79.
4. Ni Y.H. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol 2011, 46(January (1)):1-8.
5. Szmuness W., Prince A.M., Hirsch R.L., Brotman B. Familial clustering of hepatitis B infection. N Engl J Med 1973, 289(November (22)):1162-1166.
6. Lok A.S., Lai C.L., Wu P.C., Wong V.C., Yeoh E.K., Lin H.J. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987, 126(September (3)):492-499.
7. Dumpis U., Holmes E.C., Mendy M., Hill A., Thursz M., Hall A., et al. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J Hepatol 2001, 35(July (1)):99-104.
8. Prince A.M., White T., Pollock N., Riddle J., Brotman B., Richardson L. Epidemiology of hepatitis B infection in Liberian infants. Infect Immun 1981, 32(May (2)):675-680.
9. Hepatitis B FAQs for Health Professionals. Available from: [cited 21.03.11]. http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm.
10. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55(December (RR-16)):1-33. [quiz CE1-4].
11. Centers for Disease Control and Prevention Recommendation of the Immunization Practices Advisory Committee (ACIP) inactivated hepatitis B virus vaccine 1982.
12. Wong V.C., Ip H.M., Reesink H.W., Lelie P.N., Reerink-Brongers E.E., Yeung C.Y., et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984, 1(April (8383)):921-926.
13. Xu Z.Y., Liu C.B., Francis D.P., Purcell R.H., Gun Z.L., Duan S.C., et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985, 76(November (5)):713-718.
14. Esteban J.I., Genesca J., Esteban R., Hernandez J.M., Seijo G., Buti M., et al. Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. J Med Virol 1986, 18(April (4)):381-391.
15. Andre F.E., Zuckerman A.J. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994, 44(October (2)):144-151.
16. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40(November (RR-13)):1-25.
17. Recommended Immunization Schedule for Persons Aged 0 through 6 Years. Available from: [accessed 09.01.11]. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/0-6yrs-schedule-pr.pdf.
18. Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C. What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179(February (2)):489-492.
19. Hadler S.C., Margolis H.S., Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 1992, 12:282-308.
20. Centers for Disease Control and Prevention Sensitivity of the test for antibody to hepatitis B surface antigen - United States. MMWR Morb Mortal Wkly Rep 1993, 42(September (36)):707-710.
21. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989, 261(June (22)):3278-3281.
22. Lolekha S., Warachit B., Hirunyachote A., Bowonkiratikachorn P., West D.J., Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002, 20(November (31-32)):3739-3743.
23. Lee C.Y., Huang L.M., Chang M.H., Hsu C.Y., Wu S.J., Sung J.L., et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991, 10(April (4)):299-303.
24. Kabir A., Alavian S.M., Ahanchi N., Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res 2006, 36(December (4)):265-271.
25. Halliday M.L., Kang L.Y., Rankin J.G., Coates R.A., Corey P.N., Hu Z.H., et al. An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China. Int J Epidemiol 1992, 21(June (3)):564-573.
26. Assateerawatt A., Tanphaichitr V.S., Suvatte V., Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pac J Allergy Immunol 1993, 11(June (1)):85-91.
27. Milne A., West D.J., Chinh D.V., Moyes C.D., Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002, 67(July (3)):327-333.
28. Yang Y.J., Liu C.C., Chen T.J., Lee M.F., Chen S.H., Shih H.H., et al. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J 2003, 22(July (7)):584-588.
29. Soulie J.C., Devillier P., Santarelli J., Goudeau A., Vermeulen P., Guellier M., et al. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine 1991, 9(August (8)):545-548.
30. Velu V., Nandakumar S., Shanmugam S., Jadhav S.S., Kulkarni P.S., Thyagarajan S.P. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. World J Gastroenterol 2007, 13(June (22)):3084-3089.
31. Mohammad-Reza, Hassanjani-Roshan Y.Z.-P. Efficacy of HBIG and vaccine in infants of HBsAg positive carrier mothers. Arch Intern Med 2002, 5(1):21-23.
32. Sood A., Singh D., Mehta S., Midha V., Kumar R. Response to hepatitis B vaccine in preterm babies. Indian J Gastroenterol 2002, 21(March-April (2)):52-54.
33. Sadeck L.S., Ramos J.L. Immune response of preterm infants to hepatitis B vaccine administered within 24hours after birth. J Pediatr (Rio J) 2004, 80(March-April (2)):113-118.
34. Golebiowska M., Kardas-Sobantka D., Chlebna-Sokol D., Sabanty W Hepatitis B vaccination in preterm infants. Eur J Pediatr 1999, 158(April (4)):293-297.
35. Freitas da Motta M.S., Mussi-Pinhata M.M., Jorge S.M., Tachibana Yoshida C.F., Sandoval de Souza C.B. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine 2002, 20(February (11-12)):1557-1562.
36. Blondheim O., Bader D., Abend M., Peniakov M., Reich D., Potesman I., et al. Immunogenicity of hepatitis B vaccine in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998, 79(November (3)):F206-F208.
37. Belloni C., Chirico G., Pistorio A., Orsolini P., Tinelli C., Rondini G. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998, 87(March (3)):336-338.
38. Arora N.K., Ganguly S., Agadi S.N., Irshad M., Kohli R., Deo M., et al. Hepatitis B immunization in low birthweight infants: do they need an additional dose?. Acta Paediatr 2002, 91(9):995-1001.
39. Shokri F., Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine 2001, 19(August (31)):4544-4548.
40. Lee S.S., Lo Y.C., Young B.W., Wong K.H., Lim W.L. A reduced dose approach to hepatitis B vaccination for low-risk newborns and preschool children. Vaccine 1995, 13(March (4)):373-376.
41. Alikasifoglu M., Cullu F., Kutlu T., Arvas A., Tastan Y., Erginoz E., et al. Comparison study of the immunogenicity of different types and dosages of recombinant hepatitis B vaccine in healthy neonates. J Trop Pediatr 2001, 47(February (1)):60-62.
42. Madalinski K., Sylvan S.P., Hellstrom U., Mikolajewicz J., Dzierzanowska-Fangrat K. Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B vaccine. Med Sci Monit 2004, 10(January (1)):PI10-PI17.
43. Goldfarb J., Baley J., Medendorp S.V., Seto D., Garcia H., Toy P., et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994, 13(January (1)):18-22.
44. del Canho R., Grosheide P.M., Voogd M., Huisman W.M., Heijtink R.A., Schalm S.W. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol 1993, 41(September (1)):30-34.
45. Belloni C., Orsolini P., Martinetti M., Chirico G., Cerbo R.M., Comolli G., et al. Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers. New Microbiol 1993, 16(July (3)):237-244.
46. Patel D.M., Butler J., Feldman S., Graves G.R., Rhodes P.G. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr 1997, 131(October (4)):641-643.
47. Bassily S., Kotkat A., Gray G., Hyams K.C., Brown F.M., Imam I.Z., et al. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. Am J Trop Med Hyg 1995, 53(October (4)):419-422.
48. Plotkin S., Orenstein W. Vaccines 2004, Elsevier, Philadelphia. 4th ed.
49. Craxi A., Vinci M., Almasio P., Pagliaro L. Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine. Eur J Epidemiol 1989, 5(March (1)):65-69.
50. Beasley R.P., Hwang L.Y., Lee G.C., Lan C.C., Roan C.H., Huang F.Y., et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2(November (8359)):1099-1102.
51. Lee C., Gong Y., Brok J., Boxall E.H., Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006, 332(February (7537)):328-336.
52. Jilg W., Schmidt M., Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989, 160(November (5)):766-769.
53. Kim S.C., Chung E.K., Hodinka R.L., DeMaio J., West D.J., Jawad A.F., et al. Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 1997, 99(April (4)):534-536.
54. Huang F.Y., Lee P.I., Lee C.Y., Huang L.M., Chang L.Y., Hepatitis Liu S.C. B vaccination in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997, 77(September (2)):F135-F138.
55. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000, 355(February (9203)):561-565.
56. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9(March (3)):185-194.
57. Leuridan E., Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011, 53(July (1)):68-75.
58. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19(November (7-8)):877-885.
59. Ota M.O., Vekemans J., Schlegel-Haueter S.E., Fielding K., Whittle H., Lambert P.H., et al. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 2004, 22(January (3-4)):511-519.
60. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120(August (2)):e373-e381.
61. McMahon B.J., Dentinger C.M., Bruden D., Zanis C., Peters H., Hurlburt D., et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200(November (9)):1390-1396.
62. Boxall E.H., AS J., El-Shuhkri N., Kelly D.A. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004, 190(October (7)):1264-1269.
63. Ballesteros-Trujillo A., Vargas-Origel A., Alvarez-Munoz T., Aldana-Valenzuela C. Response to hepatitis B vaccine in preterm infants: four-dose schedule. Am J Perinatol 2001, 18(November (7)):379-385.
64. Bhave S., Bhise S., Chavan S.C., Naik S.S., Pusapati R.V., Bavdekar A., et al. Hepatitis B vaccination in premature and low birth weight (LBW) babies. Indian Pediatr 2002, 39(July (7)):625-631.
65. Gunn T.R., Bosley A., Woodfield D.G. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. N Z Med J 1989, 102(January (860)):1-3.
66. Junqueira A.L., Tavares V.R., Martins R.M., Frauzino K.V., da Costa e Silva A.M., Minamisava R., et al. Safety and immunogenicity of hepatitis B vaccine administered into ventrogluteal vs. anterolateral thigh sites in infants: a randomised controlled trial. Int J Nurs Stud 2010, 47(September (9)):1074-1079.
67. Kojouharova M., Teoharov P., Bahtchevanova T., Maeva I., Eginlian A., Deneva M. Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian newborns. Infection 2001, 29(December (6)):342-344.
68. Lau Y.L., Tam A.Y., Ng K.W., Tsoi N.S., Lam B., Lam P., et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992, 121(December (6)):962-965.
69. Losonsky G.A., Wasserman S.S., Stephens I., Mahoney F., Armstrong P., Gumpper K., et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999, 103(February (2)):E14.
70. Martins R.M., Bensabath G., Arraes L.C., Oliveira Mde L., Miguel J.C., Barbosa G.G., et al. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz 2004, 99(December (8)):865-871.
71. Ribeiro T.M., Azevedo R.S. Seroconversion of hepatitis B vaccine in infants related to the mother's serostatus in a community of Sao Jose dos Campos, state of Sao Paulo, Brazil. Clinics (Sao Paulo, Brazil) 2006, 61(October (5)):387-394.
72. Sapru A., Kulkarni P.S., Bhave S., Bavdekar A., Naik S.S., Pandit A.N. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study. J Trop Pediatr 2007, 53(October (5)):303-307.
73. Seto D., West D.J., Gilliam R.R., Ioli V.A., Ferrara D.K., Rich B. Antibody responses of healthy neonates of two mixed regimens of hepatitis B vaccine. Pediatr Infect Dis J 1999, 18(September (9)):840-842.
74. Tregnaghi M., Ussher J., Baudagna A.M., Calvari M., Grana G. Comparison of two recombinant hepatitis B vaccines and their interchangeability in Argentine infants. Pan Am J Public Health 2004, 15(January (1)):35-40.
75. Watanaveeradej V., Samakoses R., Kerdpanich A., Aree C., Nitayabhan S., Viputtikul K., et al. Antibody response to hepatitis B vaccine in infants of HIV-positive mothers. Int J Infect Dis 2002, 6(September (3)):240-241.
76. Yerushalmi B., Raz R., Blondheim O., Shumov E., Koren R., Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 1997, 16(June (6)):587-592.